NCT04879849View on ClinicalTrials.gov

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Carcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Pembrolizumab

IV infusion.

DRUG

TAK-676

IV infusion.

RADIATION

Image-guided radiation therapy

Radiation therapy.

Trial Locations (5)

91010-3012

Cedars Sinai Medical Center, Duarte

60637-1443

University of Chicago, Chicago

10016-4744

Laura And Isaac Perlmutter Cancer Center, New York

97213-2933

Providence Portland Medical Center, Portland

37232-0021

Vanderbilt University Medical Center, Nashville

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY